As predicted, the GLP-1 revolution has only accelerated, and this miracle drug will reshape the orthopedic landscape going forward.
Recent data reveals that GLP-1 adoption in the U.S. has exceeded expectations, with roughly 15% of the population having tried these drugs and 10% using them consistently—numbers that echo last year’s bold demand forecasts—while 50% of Americans express interest in starting them.
Beyond their well-known weight loss effects, studies emerging this month position GLP-1s as potential healthcare game-changers, showing promise in reducing orthopedic surgery rates, addiction, cancer risks, and even the pace of metabolic aging.
Research points to a likely decline in orthopedic surgery volumes in the years ahead due to these weight loss benefits, though short-term spikes may occur as more patients qualify post-weight loss. While the net effect appears to lean toward fewer surgeries, debate persists over whether some patients might face heightened fracture risks.
Overall, while GLP-1s enable some heavy obese patients to become eligible for orthopedic surgeries previously inaccessible due to high BMI, the predominant effect is a reduction in the need for such p...
